These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Advances in antiplatelet treatment for acute coronary syndromes. Eshaghian S; Shah PK; Kaul S Heart; 2010 May; 96(9):656-61. PubMed ID: 19910292 [TBL] [Abstract][Full Text] [Related]
27. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Martin MT; Spinler SA; Nutescu EA Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989 [TBL] [Abstract][Full Text] [Related]
28. Ticagrelor for acute coronary syndrome? Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770 [TBL] [Abstract][Full Text] [Related]
33. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Serebruany VL; DiNicolantonio JJ Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577 [TBL] [Abstract][Full Text] [Related]
34. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Husted S Fundam Clin Pharmacol; 2009 Feb; 23(1):1-9. PubMed ID: 19267766 [TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
36. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Wouter Jukema J; Collet JP; De Luca L Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345 [TBL] [Abstract][Full Text] [Related]
37. Prasugrel: a critical comparison with clopidogrel. Reinhart KM; White CM; Baker WL Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804 [TBL] [Abstract][Full Text] [Related]
38. Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge. Serebruany V Thromb Haemost; 2010 Feb; 103(2):415-8. PubMed ID: 20126838 [TBL] [Abstract][Full Text] [Related]
39. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347 [TBL] [Abstract][Full Text] [Related]
40. Prasugrel development - claims and achievements. Serebruany V; Shalito I; Kopyleva O Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]